Menopause is one of the most significant physiological transitions in a woman's life, yet it remains poorly understood and undertreated. The average woman spends over a third of her life in the postmenopausal stage, and the quality of that life is substantially shaped by how the transition is managed. Here is what the current evidence says.
What Menopause Actually Is
Menopause is defined as 12 consecutive months without a menstrual period, marking the end of ovarian follicular activity. The average age of natural menopause in developed countries is 51, though the perimenopause transition — the years of hormonal fluctuation leading up to the final period — typically begins in the mid-to-late 40s and can last 4-10 years.
The hormonal changes are driven by declining ovarian estrogen and progesterone production. Estrogen receptors exist throughout the body — in the brain, cardiovascular system, bones, skin, urinary tract, and vaginal tissue — which is why menopause affects so many systems simultaneously.
Perimenopause: The Transition Phase
Perimenopause is often more symptomatic than menopause itself. Hormonal fluctuations — rather than simply declining levels — drive many of the most disruptive symptoms. Cycles become irregular, sometimes shorter and heavier, sometimes longer and lighter. Ovulation becomes unpredictable. Pregnancy remains possible until 12 months after the final period.
Common perimenopausal symptoms include vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, brain fog, joint pain, and changes in libido. The severity varies enormously between individuals — roughly 20% of women have minimal symptoms, 60% have moderate symptoms, and 20% have severe symptoms that significantly impair quality of life.
Vasomotor Symptoms: Hot Flashes and Night Sweats
Hot flashes affect roughly 75% of women during the menopause transition and are the most commonly reported symptom. They result from estrogen withdrawal affecting the hypothalamic thermoregulatory center, causing it to become hypersensitive to small temperature changes. The result is a sudden sensation of heat, flushing, and sweating that typically lasts 1-5 minutes.
For most women, vasomotor symptoms peak in the first two years after the final period and gradually diminish. However, roughly 10-15% of women experience hot flashes for 10 or more years postmenopause. Night sweats — hot flashes occurring during sleep — are particularly disruptive because they fragment sleep architecture and contribute to fatigue, mood changes, and cognitive difficulties.
Hormone Replacement Therapy: The Evidence
HRT (also called menopausal hormone therapy or MHT) is the most effective treatment for vasomotor symptoms and has additional benefits for bone density, cardiovascular health when started early, and genitourinary symptoms. The evidence base has been substantially revised since the 2002 Women's Health Initiative study, which generated widespread fear about HRT that led to decades of undertreatment.
What the WHI Actually Found
The WHI studied a specific formulation (oral conjugated equine estrogen plus medroxyprogesterone acetate) in women with an average age of 63 — well past the optimal window for starting HRT. The modest increased risks found in that population do not apply to younger women starting HRT at the time of menopause. Subsequent reanalysis and newer studies have consistently shown that HRT started within 10 years of menopause or before age 60 has a favorable benefit-risk profile for most women.
Benefits of HRT
- Vasomotor symptoms: 75-90% reduction in hot flash frequency and severity
- Bone density: Prevents the accelerated bone loss that occurs in the first 5-10 years postmenopause; reduces fracture risk by 25-30%
- Cardiovascular health: When started within 10 years of menopause, associated with reduced cardiovascular disease risk (the "timing hypothesis")
- Genitourinary syndrome: Local estrogen therapy highly effective for vaginal dryness, urinary urgency, and recurrent UTIs
- Mood and cognition: Evidence for improved mood and reduced depression risk; cognitive effects are more complex and timing-dependent
Risks and Contraindications
HRT is not appropriate for women with a history of hormone-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, or personal history of blood clots (with some exceptions for transdermal formulations). The breast cancer risk associated with combined HRT is real but modest — comparable to the risk from drinking one glass of wine daily or being overweight. The decision requires individualized discussion with a healthcare provider.
Non-Hormonal Options
For women who cannot or choose not to use HRT, several non-hormonal options have evidence for vasomotor symptom management:
- SSRIs/SNRIs: Paroxetine (the only FDA-approved non-hormonal treatment for hot flashes), venlafaxine, and escitalopram reduce hot flash frequency by 40-60%
- Gabapentin: Effective for hot flashes, particularly night sweats; useful for women with sleep disruption
- Fezolinetant: A newer neurokinin B receptor antagonist specifically targeting the thermoregulatory pathway; approved in 2023 with strong efficacy data
- Cognitive behavioral therapy: CBT for menopause has good evidence for reducing the distress associated with hot flashes even when it does not reduce their frequency
Long-Term Health After Menopause
The postmenopausal years bring increased risk of several conditions that require proactive management:
- Osteoporosis: Bone density screening (DEXA scan) recommended at 65, or earlier for women with risk factors. Weight-bearing exercise, adequate calcium and vitamin D, and HRT or bisphosphonates when indicated
- Cardiovascular disease: Becomes the leading cause of death in postmenopausal women. Lipid management, blood pressure control, and lifestyle factors become increasingly important
- Genitourinary syndrome of menopause (GSM): Affects up to 50% of postmenopausal women and, unlike vasomotor symptoms, does not improve without treatment. Local vaginal estrogen is safe and highly effective